Back to top

Image: Bigstock

Danaher Corp.

Read MoreHide Full Article

Year-to-date, Danaher’s shares have outperformed the industry’s average return. The company has an excellent earnings history over the trailing four quarters, beating estimates all through. We are optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Going forward, the company expects the biopharma business to be a major growth driver. Its recent acquisitions - Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues. However, on the flip side, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business has restricted growth. Weakness in industrial markets and stiff competition may also hurt the company's financials.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Danaher Corporation (DHR) - free report >>

Published in